Loading…
Omeros Corporation is projected to rise to $14.38 by 2027, a +30% move from its current price of $11.07. OMER is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $10.71 | $11.07 | $11.45 | +0.04% |
| May 30 | $10.57 | $11.08 | $11.62 | +0.08% |
| May 31 | $10.46 | $11.08 | $11.74 | +0.12% |
| Jun 1 | $10.37 | $11.09 | $11.85 | +0.16% |
| Jun 2 | $10.29 | $11.09 | $11.95 | +0.20% |
| Jun 3 | $10.22 | $11.10 | $12.04 | +0.24% |
| Jun 4 | $10.16 | $11.10 | $12.13 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.16 | $11.10 | $12.13 | +0.28% |
| Week 2 | $9.82 | $11.13 | $12.62 | +0.56% |
| Week 3 | $9.58 | $11.16 | $13.01 | +0.84% |
| Week 4 | $9.38 | $11.19 | $13.36 | +1.12% |
| Week 5 | $9.21 | $11.23 | $13.68 | +1.40% |
| Week 6 | $9.06 | $11.26 | $13.98 | +1.68% |
| Week 7 | $8.93 | $11.29 | $14.26 | +1.97% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Omeros Corporation is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder.
In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Omeros Corporation (OMER) trades at $11.46 per share and has a market cap of $829.42M, ranking 2667 by market size. The stock sits in the healthcare sector, with a portfolio focused on immunologic diseases and complement pathway therapeutics. The current price, combined with its multi-year forecast, suggests a path of upside with notable advances in later years.
The 2026 average price is $11.46, and the forecast progresses to a 2050 average of $73.87, signaling meaningful long-run appreciation alongside bullish sentiment beginning in 2027. These figures are estimates and not guarantees, and actual results will depend on market conditions and company developments.
A major floor 24.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 36.0% above — a clean break opens room to run.
A major ceiling 48.1% above — clearing it would confirm fresh momentum.
Key OMER support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OMER market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.70 | Sell | $11.63 | Sell |
| MA 10 | $12.21 | Sell | $12.18 | Sell |
| MA 20 | $13.44 | Sell | $12.72 | Sell |
| MA 50 | $12.45 | Sell | $12.63 | Sell |
| MA 100 | $12.25 | Sell | $11.87 | Sell |
| MA 200 | $9.64 | Buy | $10.35 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.93 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -119.46 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.38 | Sell |
| ROC (12) | -21.66 | Sell |
| Bollinger %B (20,2) | 0.08 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.00 | Sell |
| Awesome (5,34) | -1.54 | Sell |
| Ultimate (7,14,28) | 29.50 | Buy |
| Momentum (10) | -3.69 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 11.30 | Sell |
| ADX (14) | 26.80 | Sell |
| ATR (14) | 0.41 | Info |
The 30-day technical picture shows a neutral stance with RSI14 at 40, indicating subdued near-term momentum. The stock trades around the SMA50 of $12.45 and above the SMA200 of $9.57, placing it between key moving averages. Immediate support is at $11.38 and resistance at $15.06, with a 30-day price range from $9.18 to $14.31.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.81 | $11.07 | $16.21 | 0% | Neutral | |
| $11.16 | $14.38 | $19.78 | +30% | Bullish | |
| $11.79 | $15.72 | $22.55 | +42% | Bullish | |
| $11.50 | $15.79 | $23.42 | +43% | Bullish | |
| $12.15 | $17.11 | $26.10 | +55% | Bullish | |
| $12.16 | $17.53 | $27.40 | +58% | Bullish | |
| $13.57 | $19.99 | $31.94 | +81% | Bullish | |
| $17.03 | $25.63 | $41.77 | +132% | Bullish | |
| $18.04 | $27.69 | $45.95 | +150% | Bullish | |
| $18.04 | $28.22 | $47.64 | +155% | Bullish | |
| $25.05 | $42.80 | $77.52 | +287% | Bullish | |
| $35.10 | $70.16 | $140.68 | +534% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $9.81 | $11.07 | $12.98 | +0.00% |
| June 2026 | $9.28 | $10.96 | $13.28 | -1.02% |
| July 2026 | $9.63 | $11.48 | $14.14 | +4.76% |
| August 2026 | $9.72 | $11.68 | $14.57 | +1.77% |
| September 2026 | $9.58 | $11.60 | $14.61 | -0.72% |
| October 2026 | $9.91 | $12.07 | $15.35 | +4.08% |
| November 2026 | $10.33 | $12.64 | $16.21 | +4.74% |
| December 2026 | $10.19 | $12.55 | $16.21 | -0.75% |
Click any year to see its month-by-month OMER forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The OMER price prediction for 2026 points to an average of $11.07 (low $9.81, high $16.21) — a potential gain of 0% on today's $11.07. Price action looks broadly range-bound.
In 2027, OMER is projected to trade between $11.16 and $19.78, averaging $14.38 — a potential gain of +30% from today's $11.07. That is up +30% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Omeros Corporation's 2028 outlook centres on $15.72, within a $11.79 to $22.55 range. That is up +9% on the projected 2027 average. That marks a +42% change versus current levels. Momentum favours further upside here.
By 2029, OMER could reach as high as $23.42, with a base case around $15.79 and support toward $11.50 — roughly +43% from $11.07. Buyers look set to stay in control over this stretch.
Expect OMER to range from $12.15 to $26.10 through 2030. The $17.11 average target implies a +55% move from current prices. That is up +8% on the projected 2029 average. Momentum favours further upside here.
The OMER price prediction for 2031 points to an average of $17.53 (low $12.16, high $27.40) — a potential gain of +58% on today's $11.07. Buyers look set to stay in control over this stretch.
In 2032, OMER is projected to trade between $13.57 and $31.94, averaging $19.99 — a potential gain of +81% from today's $11.07. That is up +14% on the projected 2031 average. Momentum favours further upside here.
Omeros Corporation's 2033 outlook centres on $25.63, within a $17.03 to $41.77 range. That is up +28% on the projected 2032 average. That marks a +132% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, OMER could reach as high as $45.95, with a base case around $27.69 and support toward $18.04 — roughly +150% from $11.07. Momentum favours further upside here.
Expect OMER to range from $18.04 to $47.64 through 2035. The $28.22 average target implies a +155% move from current prices. That is up +2% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The OMER price prediction for 2040 points to an average of $42.80 (low $25.05, high $77.52) — a potential gain of +287% on today's $11.07. Momentum favours further upside here.
In 2050, OMER is projected to trade between $35.10 and $140.68, averaging $70.16 — a potential gain of +534% from today's $11.07. That is up +64% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in OMER today (≈ 90.334237 OMER) could be worth
$6,337.79
+$5,337.79 (+534%) by 2050 · US Dollar
Based on the average projected OMER price of $70.16 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OMERwould be worth at today's price.
$1,000 invested in OMER on May 27, 2025 (≈ 315.457406 OMER) would be worth
$3,492.11
+$2,492.11 (+249.2%) today · 3.49× · US Dollar
Based on a OMER entry price of $3.17 vs. today's $11.07.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.38 | $894.18 | -10.6% |
| 1 month ago | $14.74 | $751.02 | -24.9% |
| 3 months ago | $11.55 | $958.44 | -4.2% |
| 6 months ago | $9.69 | $1,142.41 | +14.2% |
| 1 year ago | $3.17 | $3,492.11 | +249.2% |
| All time (5.0y) ago | $15.35 | $721.17 | -27.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OMER forecast.
Our base-case forecast reaches $22.00 around 2033.
Implied market cap at $22.00: $1.59B
Looking further out, the forecast is increasingly bullish. The 2026 average price is $11.46 with an ROI of 0%. In 2027 the average rises to $14.97 (ROI 30.6%), 2028 to $16.42 (ROI 43.3%), and 2029 to $16.37 (ROI 42.8%), with 2030 averaging $17.92 (ROI 56.4%).
The momentum continues into 2031 at $18.38 (ROI 60.4%), 2032 at $20.93 (ROI 82.6%), 2033 at $27.18 (ROI 137.2%), 2034 at $29.14 (ROI 154.3%), and 2035 at $29.44 (ROI 156.9%). The long horizon shows substantial upside: 2040 at $45.37 (ROI 295.9%) and 2050 at $73.87 (ROI 544.6%), with sentiment remaining bullish. These figures are estimates and not guarantees, and they depend on numerous factors including market conditions and clinical developments.
Tap a question to reveal the answer.
In 2030, the average price is forecast to be $17.92 with an ROI of 56.4%.
The forecast shows bullish sentiment starting in 2027, with 2027 average $14.97 (ROI 30.6%), 2028 average $16.42 (ROI 43.3%), 2030 average $17.92 (ROI 56.4%), 2040 average $45.37 (ROI 295.9%), and 2050 average $73.87 (ROI 544.6%). These are estimates and not guarantees.
Yes, the max forecast values suggest $49.81 in 2035 and $82.38 in 2040, indicating a path to $50 by 2040 at the latest based on the presented max values.
The current price is $11.46.
The 2050 average price is $73.87 with an ROI of 544.6%, and the sentiment is bullish.
Omeros Corporation Community Discussion
0Share your Omeros Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.